{"id":90743,"date":"2016-12-05T16:39:02","date_gmt":"2016-12-05T16:39:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=90743"},"modified":"2016-12-05T16:39:02","modified_gmt":"2016-12-05T16:39:02","slug":"stroke-market-product-development-competitor-information-analysis-and-report-insights-2016","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/stroke-market-product-development-competitor-information-analysis-and-report-insights-2016_90743.html","title":{"rendered":"Stroke Market Product Development, Competitor Information, Analysis and Report Insights 2016"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“ReportsWeb”<\/div>\n<\/div>\n<\/div>\n
ReportsWeb.com has announced the addition of the \u201cStroke – Pipeline Review, H2 2016\u201d provides an overview of the Stroke (Cardiovascular) pipeline landscape.<\/div>\n

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. <\/p>\n

Report Highlights
<\/strong>
Publisher’s Pharmaceutical and Healthcare latest pipeline guide Stroke – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.<\/p>\n

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND\/CTA Filed, Preclinical and Discovery stages are 1, 10, 21, 14, 1, 89 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 35 and 4 molecules, respectively.Stroke.<\/p>\n

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.<\/p>\n

For more information about this report at<\/strong> http:\/\/www.reportsweb.com\/stroke-pipeline-review-h2-2016<\/strong><\/a><\/p>\n

Report Scope<\/strong>
<\/strong>
– The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities\/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
– The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)<\/p>\n

Request a sample copy at<\/strong> http:\/\/www.reportsweb.com\/inquiry&RW0001492645\/sample<\/strong><\/a><\/p>\n

Reasons to buy<\/strong>
<\/strong>
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.<\/p>\n

Key Company profiles <\/strong><\/p>\n

AB Science SA 
Acticor Biotech 
ActiveSite Pharmaceuticals Inc
Addex Therapeutics Ltd
advanceCor GmbH
Affibody AB 
Amarantus Bioscience Holdings Inc
Anavex Life Sciences Corp
Angion Biomedica Corp
Antoxis Ltd 
APT Therapeutics, Inc.
ArmaGen Inc 
Asterias Biotherapeutics, Inc.
AstraZeneca Plc
Athersys Inc 
Bayer AG 
Bioasis Technologies Inc
Biogen Inc 
Boehringer Ingelheim GmbH
Cardax Inc 
Cellular Biomedicine Group Inc
CHA Bio & Diostech Co Ltd
ContraVir Pharmaceuticals Inc
CSPC Pharmaceutical Group Limited
D-Pharm Ltd 
Daiichi Sankyo Company Ltd
DiaMedica Inc 
Diffusion Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Fina Biotech 
Genervon Biopharmaceuticals LLC
Glialogix Inc 
Glucox Biotech AB
Green Cross Corp
Huons Co Ltd 
International Stem Cell Corp
Jeil Pharmaceutical Co Ltd
JN-International Medical Corp
Laboratoires Pierre Fabre SA
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Living Cell Technologies Ltd
Lumosa Therapeutics Co Ltd
M et P Pharma AG
Magnus Life Ltd 
Mapreg SAS 
Mast Therapeutics Inc
Medestea Research & Production SpA
Mitochon Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Neuralstem Inc 
Neuren Pharmaceuticals Ltd
Neurofx Inc 
Neuronax SAS 
Neurotec Pharma SL
NeuroVive Pharmaceutical AB
New Haven Pharmaceuticals, Inc.
New World Laboratories Inc
NoNO Inc 
NuvOx Pharma LLC
Omeros Corp 
Panacea Pharmaceuticals Inc
PharmatrophiX, Inc.
Pharmaxis Ltd 
Pharmicell Co Ltd 
Phoenix Biotechnology Inc
Phylogica Ltd 
PhytoHealth Corp 
Pluristem Therapeutics Inc
Primary Peptides, Inc.
Q Therapeutics Inc
QR Pharma Inc 
ReCyte Therapeutics Inc
Regenera Pharma Ltd
RegeneRx Biopharmaceuticals Inc
Remedy Pharmaceuticals Inc
ReNeuron Group Plc
SanBio Inc 
Saneron CCEL Therapeutics Inc
Shin Poong PharmCo Ltd
Simcere Pharmaceutical Group
Stemedica Cell Technologies Inc
SynZyme Technologies LLC
Targazyme Inc 
The International Biotechnology Center (IBC) Generium
TikoMed AB 
vasopharm GmbH
Verseon Corp 
Vicore Pharma AB
Virogenomics BioDevelopment Inc
WhanIn Pharmaceutical Co Ltd
Zocere Inc<\/p>\n

Ask for Discount at <\/strong>http:\/\/www.reportsweb.com\/inquiry&RW0001492645\/discount<\/strong><\/a><\/p>\n

List of Figures<\/strong>
<\/strong>
Number of Products under Development for Stroke, H2 2016 29
Number of Products under Development for Stroke – Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities\/Institutes, H2 2016 39
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Products, H2 2016 43
Assessment by Monotherapy Products, H2 2016 148
Number of Products by Top 10 Targets, H2 2016 149
Number of Products by Stage and Top 10 Targets, H2 2016 149
Number of Products by Top 10 Mechanism of Actions, H2 2016 155
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 155
Number of Products by Top 10 Routes of Administration, H2 2016 161
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161
Number of Products by Top 10 Molecule Types, H2 2016 163
Number of Products by Stage and Top 10 Molecule Types, H2 2016 163<\/p>\n

Purchase Complete Report at <\/strong>http:\/\/www.reportsweb.com\/buy&RW0001492645\/buy\/2000<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> ReportsWeb
Contact Person:<\/strong> Rajat Sahni
Email:<\/strong> sam@reportsweb.com
Phone:<\/strong> +1-646-491-9876
Country:<\/strong> India
Website:<\/strong> http:\/\/www.reportsweb.com\/stroke-pipeline-review-h2-2016<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“ReportsWeb” ReportsWeb.com has announced the addition of the \u201cStroke – Pipeline Review, H2 2016\u201d provides an overview of the Stroke (Cardiovascular) pipeline landscape. Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-90743","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=90743"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90743\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=90743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=90743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=90743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}